Indication: 1. Hyperlipidemia (1) For patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, when dietary control and other non-drug treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides. Simvastatin also increases high-density lipoprotein cholesterol, thereby reducing the ratio of low-density lipoprotein/high-density lipoprotein and total cholesterol/high-density lipoprotein. (2) For patients with homozygous familial hypercholesterolemia, when dietary control and non-dietary treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. 2. Coronary heart disease. (1) Reduce the risk of death. (2) Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction. (3) Reduce the risk of stroke and transient ischemic attack. (4) Reduce the risk of myocardial revascularization surgery (coronary artery bypass grafting and percutaneous balloon coronary angioplasty). (5) Delay the progression of atherosclerosis, including the occurrence of new lesions and complete blockage.

Indication: 1. Hyperlipidemia (1) For patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, when dietary control and other non-drug treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides. Simvastatin also increases high-density lipoprotein cholesterol, thereby reducing the ratio of low-density lipoprotein/high-density lipoprotein and total cholesterol/high-density lipoprotein. (2) For patients with homozygous familial hypercholesterolemia, when dietary control and non-dietary treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. 2. Coronary heart disease. (1) Reduce the risk of death. (2) Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction. (3) Reduce the risk of stroke and transient ischemic attack. (4) Reduce the risk of myocardial revascularization surgery (coronary artery bypass grafting and percutaneous balloon coronary angioplasty). (5) Delay the progression of atherosclerosis, including the occurrence of new lesions and complete blockage.

Indication: Used as an auxiliary treatment for coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness.

Indication: Used as an auxiliary treatment for coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness.

Indication: It can be used as an auxiliary treatment for coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, sudden deafness and ischemic cerebrovascular disease, viral myocarditis in children, diabetes, etc.

Indication: Used as an auxiliary treatment for coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness.

Indication: Used as an auxiliary treatment for coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness.

Indication: Used as an auxiliary treatment for coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness.

Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3 to 6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.

Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3 to 6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.